This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Current clinicaltrials are investigating: Precision dosing based on genetic markers Personalized cannabinoid ratios for specific conditions Combination therapies with other natural compounds Long-term safety and efficacy data Is Microdosing Right for You?
Clinicaltrials have been looking into both THC and CBD and their individual roles in treating anxiety. Also, therapy or talking to a professional can be incredibly helpful in tackling the root causes of anxiety. Safety first! But high doses? Well, they can sometimes have the opposite effect. The takeaway?
Now, patients affected by TRD – who didn’t respond to at least two other antidepressants – no longer need to use an antidepressant in order to benefit from ketamine-based therapy. If you are curious about ketamine therapy for depression, you may still have questions, such as: How is ketamine different from other antidepressants?
Federal health regulators recently declined to approve the use of the psychedelic drug midomafetamine (3,4-methylenedioxymethamphetamine or MDMA) as a treatment for post-traumatic stress disorder (PTSD), disappointing many advocates who were hopeful for the next breakthrough in the psychedelic therapy movement.
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. . This relationship enables us to initiate our clinical research program and marks an important step for Wake in Canada. ABOUT SANTÉ CANNABIS.
IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinicaltrial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.
INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.
Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. So far, science is telling us that yes cannabis has anti-seizure actions. References Staff, T.
While conventional therapies such as psychotherapy and medications are widely used, they do not uniformly alleviate symptoms for all individuals. Conventional treatments for PTSD primarily include psychotherapy, such as cognitive behavioral therapy, and medications like antidepressants and anti-anxiety drugs.
Psilocybin , a psychedelic compound found in a variety of mushrooms, has long been used as a tool to mitigate depression despite the limited amount of research on its efficacy and safety. While 233 participants might sound low, it is still the largest number of humans to participate in a psilocybin-based clinicaltrial.
The Financing will allow the Company to continue progressing its R&D, clinicaltrials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinicaltrials in early 2022,” said CEO, Josh Bartch. DENVER, Dec.
In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care. However, it is also being used for off-label infusions for the management of psychiatric disorders and chronic pain management (enter the clinics).
Their position as therapeutic practitioners, as well as their work in conducting the kind of clinicaltrials necessary to advance regulatory outcomes for psychedelic medicines, make them ideal partners in alignment with Optimi’s strategic goals.”. VANCOUVER, British Columbia, July 13, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (
Highlights: Phase IIb COMP360 psilocybin therapytrial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79
For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinicaltrial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinicaltrial.
“The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinicaltrials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.
MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. MAPS Public Benefit Corporation will coordinate trial design with Medicines and Healthcare products Regulatory Agency to create a road map for early patient access in the UK. Corine de Boer, M.D.,
New therapy exploration suggest potential in using psilocybin for OCD symptoms. And it further reinforces the need to carry out clinicaltrials to determine the safety and efficiency of using psilocybin to treat OCD. This discovery adds to the ongoing research on the medical use of psychedelics in psychiatry.
Medical cannabis was legally approved in Germany in 2017 when approval was given for therapy-resistant symptoms in severely affected patients independent of diagnosis and without clinical evidence-based data,” lead investigator Professor Carsten Buhmann of the University Medical Center Hamburg-Eppendorf explained in a statement.
INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.
5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a ClinicalTrial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinicaltrial for INM-755 in healthy volunteers. VANCOUVER, Nov.
– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. Additionally, this novel antibody conjugate demonstrated very good tolerability during this DLT phase 1 trial. Clinicaltrial information: NCT03276572 ( [link] ). Abstract Number: 5015.
(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinicaltrial for IGC-AD1. The results of the clinicaltrial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.
Revenue share payments will be based on North America sales of MDMA for use in MDMA-assisted therapy, will terminate after 8 years, and include a reciprocity payment structure that reduces payments once certain financial milestones are met.
Disease-modifying therapies (DMTs) are essential in altering the immune response to reduce inflammation and prevent further damage to the nervous system. Additionally, no current treatments can reverse existing neurological damage, highlighting the need for ongoing research into more effective therapies and potential cures.
The use of psychedelic substances to treat mental illness and physical disorders is known as “psychedelic therapy.” In a typical scenario, psychedelic substances would be used in conjunction with psychotherapy sessions to treat disorders for which other medicinal therapies have failed. Psychedelic therapy is not a fringe phenomenon.
I look forward to a time when they are not considered alternative therapies or home remedies but actually first-line therapies,” said the CEO of Zelira, Oludare Odumosu. “We Additionally, numerous other cannabis-based medications have already gained approval or are in the process of being tested in clinicaltrials.
However, health professionals have been reluctant to prescribe cannabis-based medicines in the UK because of the lack of clinicaltrial evidence of its benefits and safety. This would answer questions about safety and efficacy, they said. The final guideline is expected to be published in November 2019.
Natural plant therapy , and cannabis specifically, has been studied for its effectiveness in alleviating and treating many of these physiological and emotional symptoms that come into play with a terminal illness. One study from the Journal of Clinical Oncology examined the efficacy of cannabinoids in appetite stimulation.
(OTC: EHVVF) adds Dr. Jeffrey Kamlet, an expert on cardiac safety in ibogaine treatment, as Chief Medical Officer. retains CRO Sante Cannabis to conduct clinicaltrials in psilocybin therapies. Press Release. Entheon Biomedical Corp. CSE: ENBI) announces agreement to acquire Lobo Genetics Inc. Press Release.
The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinicaltrials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. MEDIA CONTACT .
as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. At 36, MAPS is now older than I was when I started MAPS at age 32.
Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. So far, science is telling us that yes cannabis has anti-seizure actions. References Staff, T.
In this article, we explore the role of medical marijuana in addressing insomnia, examining its effectiveness, safety considerations, legal aspects, and practical considerations for patients and healthcare providers. Medical marijuana is a potential treatment for insomnia, and it offers an alternative to traditional pharmaceuticals.
According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.”
For example, most, if not all, states have legalized the use of medical marijuana to treat specific health conditions for which there is no or only poor quality clinical evidence of efficacy and safety. Who monitors their health and the long-term effects of the marijuana therapy?
. “As MMJ International Holdings continues to advance to its clinicaltrials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development.
Clinicaltrials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency identified psilocybin as a breakthrough for treatment-resistant depression. The Project.
Those values guide our joint efforts to change perceptions about psychedelic assisted therapies, raise awareness of the scientific advances and, ultimately, bring better health to European citizens. Ketamine is already registered for the treatment of depression and in 2023, the FDA might approve an MDMA assisted therapy for PTSD.
The researchers stated that these knowledge gaps must be addressed and that “clinicaltrial data about how medical cannabis improves patient quality of life domains is desperately needed as this information can impact clinical decision-making.”.
Following the execution of this work, cbdMD Therapeutics will perform the requisite toxicological studies with Ion Tox, a leading in vitro toxicology and ADME-PK testing company, to support the safety of the cannabinoids of interest.
The highest quality form of scientific research, in terms of whether the results provide predictive power (which is what science is all about), is the placebo controlled, double blind, randomized clinicaltrial. Non-clinical research can help answer questions regarding safety and risk in very powerful ways.
North American Industry Leader in Psychedelic Therapy and Research. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Shared mission of responsibly reintroducing psychedelic therapy to mental healthcare.
Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). What are the common adverse events noted in clinicaltrials examining the efficacy of cannabinoids for ASD?
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content